Neonatal hemolytic anemia does not always indicate thalassemia: a case report.

BMC Res Notes

Department of Medicine, School of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.

Published: September 2017

AI Article Synopsis

  • Congenital erythropoietic porphyria (CEP) is a rare genetic disorder caused by a defect in heme-porphyrin synthesis, leading to skin, bone, and cartilage damage, as well as symptoms like reddish urine and hemolytic anemia.
  • A 5-year-old boy from a Middle Eastern background was initially misdiagnosed with alpha thalassemia but later presented with skin lesions, red urine, and hepatosplenomegaly, prompting further testing.
  • The case highlights the delay in diagnosing CEP, which was not recognized until age 5, despite its clear symptoms being present since birth, illustrating the importance of accurate genetic evaluation in cases of hemolytic anemia.

Article Abstract

Background: Congenital erythropoietic porphyria is a rare autosomal recessive disorder that affects heme-porphyrin synthesis. This disorder is due to the genetic defect of uroporphyrinogen III cosynthase. This defect results in the accumulation of high amounts of uroporphyrin I in all tissues, leading to clinical manifestations ranging from mild to severe chronic damage of the skin, cartilage and bone. Hypertrichosis, erythrodontia and reddish-colored urine are often present, as well as hemolytic anemia accompanied by hepatosplenomegaly.

Case Presentation: Here, we present a case of a 5-year-old male child of Middle Eastern origin who had been diagnosed as having alpha thalassemia and was undergoing chronic blood transfusions. He later presented with hypopigmented skin lesions and atrophy post-photosensitivity, persistent red-colored urine and hepatosplenomegaly. Laboratory investigations showed a high level of porphyrin metabolites in his plasma and erythrocytes. As a result, he was diagnosed as having Congenital erythropoietic porphyria.

Conclusion: Here, we diagnose a case of congenital erythropoietic porphyria which was initially missed, although the clinical features were clear (red-colored urine, hepatosplenomegaly and hemolytic anemia were present since birth, and skin manifestations appeared at the age of 22 months after being exposed to sunlight). After a DNA test was performed, the patient was initially diagnosed as having alpha thalassemia. We identified two causes of hemolytic anemia (congenital erythropoietic porphyria and alpha thalassemia) in this patient. The diagnosis of congenital erythropoietic porphyria was missed up until the child turned 5 years old. To our knowledge, this is the first case of hemolytic anemia to be reported with a diagnosis of both congenital erythropoietic porphyria and alpha thalassemia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596485PMC
http://dx.doi.org/10.1186/s13104-017-2803-6DOI Listing

Publication Analysis

Top Keywords

congenital erythropoietic
24
hemolytic anemia
20
erythropoietic porphyria
20
alpha thalassemia
16
diagnosed alpha
8
red-colored urine
8
urine hepatosplenomegaly
8
porphyria alpha
8
diagnosis congenital
8
congenital
6

Similar Publications

Reduced GATA1 levels are associated with ineffective erythropoiesis in sickle cell anemia.

Haematologica

December 2024

Red Cell Haematology Lab, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London.

Ineffective erythropoiesis (IE) is defined as the abnormal differentiation and excessive destruction of erythroblasts in the marrow, accompanied by an expanded progenitor compartment and relative reduction in the production of reticulocytes. It is a defining feature of many types of anemia, including beta-thalassemia. GATA1 is an essential transcription factor for erythroid differentiation, known to be implicated in hematological conditions presenting with IE, including beta-thalassemia and congenital dyserythropoietic anemia.

View Article and Find Full Text PDF

Background: Congenital sideroblastic anemia (CSA) constitutes a group of inherited erythropoietic disorders. Some affect mainly or exclusively erythroid cells; other syndromic forms occur within multisystem disorders with extensive nonhematopoietic manifestations. In this study, we have performed clinical and molecular investigations on a 10-year-old boy suspected of having CSA.

View Article and Find Full Text PDF
Article Synopsis
  • A young anemic woman developed liver failure and swelling after taking ferrous sulfate, leading to the discovery of her congenital erythropoietic porphyria (CEP) through a skin exam and lab tests.
  • She received treatment that included IV methylprednisolone, blood transfusions, vitamins, and wound care.
  • The report highlights the need for doctors to be aware of CEP, as it can be mistaken for other conditions and reactions due to its rarity.
View Article and Find Full Text PDF
Article Synopsis
  • X-linked sideroblastic anemia (XLSA) and X-linked protoporphyria (XLPP) are rare genetic diseases caused by mutations affecting the enzyme ALAS2, crucial for heme production, with XLSA resulting from loss-of-function and XLPP from gain-of-function mutations.
  • Researchers created knockin mouse models using CRISPR-CAS9 to study these diseases along with a model for congenital sideroblastic anemia (CSA) linked to SLC25A38 mutations, allowing for in-depth examination of disease characteristics and responses to dietary vitamin B6.
  • The study revealed varying sensitivities to pyridoxine deficiency across models, highlighting a unique lethal interaction between certain sideroblastic anemias and vitamin
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!